Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LOX | P28300 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6904251 | 0.99 | MAPK8 (0.57) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4082338 | 0.90 | MAPK8 (0.55) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL8352585 | 0.88 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4086682 | 0.88 | MAPK8 (0.52) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4082313 | 0.86 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL4459782 | 0.86 | MAPK8 (0.53) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL6454278 | 0.85 | MAPK8 (0.49) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL7313604 | 0.83 | MAPK8 (0.67) | MAPK8HPGDKMT2A | |
| SCHEMBL5258696 | 0.83 | MAPK8 (0.47) | MAPK8HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL7399781 | 0.80 | MAPK8 (0.57) | MAPK8HPGDLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476157-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6756392-B2 | CARBOCYCLIC SECONDARY AMIDES SUCH AS 2-(4-FLUORO-PHENOXY) -N-(4-((2-HYDROXY-3-METHYL-BENZOYL AMINO)-METHYL)-BENZYL)-NICOTINAMIDE, ADMINISTERED FOR PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS | PFIZER INC | 2004-06-29 | — | — | US | disclosed |
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | MAGEE THOMAS V (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003068234-A1 | NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068232-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068232-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | MAPK8 1524/4885HPGD 32/4885LMNA 1996/4885 |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | NNMT, IL5, HNMT | MAPK8 4288/4885HPGD 64/4885LMNA 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.